Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin’s Phozevel Now Available for Hyperphosphatemia
February 20, 2024
- Daiichi Sankyo’s TROP2 ADC Now under US FDA Review for Lung Cancer
February 20, 2024
- Active Pharma Hid Botched API Production, Source Reveals Details of Violations
February 19, 2024
- Sawai Group President Says US Biz Exit was Due to Lack of Foresight
February 19, 2024
- Vital KSK, 3 Other Firms Invest in LinDo to Drive Japan Launch of Innovative Drugs
February 19, 2024
- Astellas, Kelonia Join Hands to Develop In Vivo Cell Therapies
February 19, 2024
- UCB Rolls Out gMG Drug Zilbrysq in Japan
February 19, 2024
- Sandoz Launches Promotion for Humira Biosimilar in Japan
February 19, 2024
- Japan Awards Priority Review for Keytruda/Padcev in Bladder Cancer: Astellas
February 19, 2024
- Otsuka’s IgA Nephropathy Drug Gets FDA Breakthrough Tag
February 19, 2024
- SC Autoinjector Pen Versions of Metoject Approved in Japan: Eisai/Medac
February 16, 2024
- Evrysdi Filed for Pre-Symptomatic SMA in Japan: Chugai
February 16, 2024
- Cancer Specialist BeiGene Set to Enter Japan Market as Early as This Year
February 16, 2024
- Ono Strikes New Oncology Pact with Numab
February 15, 2024
- Takeda Files Immunoglobulin Hyqvia in Japan
February 15, 2024
- Otsuka’s 2023 Pharma Sales Climb 20% on 4 Global Brands
February 15, 2024
- GSK Japan Nets 11% Sales Rise in 2023, Sees 6% CAGR through 2026: President
February 15, 2024
- CureApp’s Therapeutic App Makes Mark in PIII Alcohol Reduction Study
February 14, 2024
- Ono, Shattuck Ink Drug Discovery Collab on Bifunctional Fusion Proteins
February 14, 2024
- Takeda Earns US Nod for Oral EoE Drug after Resubmission
February 14, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…